DrugBank

AUGUST 15, 2024

Drug development is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. Improved Return on Investment (ROI) Industry-academic partnerships can enhance the financial return on drug development investments.

Drug Development 80

Drug Development Clinical Trials Drugs Therapies 80

The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide.

Licensing 52

Licensing Licensing Production Drug Development 52

Perficient: Drug Development

OCTOBER 20, 2023

While it proved to be tricky to find an opening for an infant, we endeavored to compare in-home daycares and licensed facilities. In contrast, the licensed facilities we used maintained extended afternoon hours, providing a tad more flexibility for evening pickups. Luckily, Perficient is very family friendly.

Licensing 52

Licensing Licensing Doctors Regulations 52

Perficient: Drug Development

AUGUST 13, 2024

Cost Management and Optimization One of the key advantages of cloud migration is the potential for significant cost savings and licensing cost avoidance. Our team continuously monitors and optimizes your infrastructure, helping you to maximize the return on your cloud investment.

Licensing 52

Licensing Licensing 52

Drug Target Review

SEPTEMBER 5, 2024

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company. I experienced challenges in cultural differences working with US, UK, Japan, and China.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

ASPET

OCTOBER 12, 2023

To maintain cadence with looming threats in a prolonged field care environment, the broader medical countermeasure (MCM) enterprise must adopt new strategies for CBRN-addressing drug development. Repurposing is one such method.

Therapies 100

Therapies Licensing Licensing FDA Approval 100

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

Drug Target Review

MARCH 17, 2025

This concept is crucial in early drug discovery because it challenges traditional methods of drug development, where the focus is often on the PK. Donello has led numerous international scientific collaborations, acquisition integrations, and the in-licensing and out-licensing of various drug programmes.

Treatment 52

Treatment Licensing Licensing Science 52

Drug Target Review

NOVEMBER 25, 2024

I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development. Personally, I went from working in licensing and business development in big pharma straight to being a CEO. Gender diversity is a hot topic in pharmaceutical and biotech drug development.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

Drug Patent Watch

MARCH 25, 2020

This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported License. link] Drug developers require access to scientific information in….

Licensing 69

Licensing Licensing Drugs Drug Development 69

The Pharma Data

DECEMBER 3, 2020

TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. TAIPEI , Dec.

Licensing 52

Licensing Licensing DNA Regulations 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Licensing 52

Licensing Licensing Therapies Science 52

Drug Target Review

DECEMBER 11, 2024

This issue poses a significant hurdle for drug developers, with no universal protocol currently in place to address these complexities. Despite these advancements, analysing biologically derived targets remains a formidable challenge due to interference from endogenous molecules.

International 52

International Laboratories Drugs Pharmacokinetics 52

Advarra

AUGUST 10, 2023

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

Drug Development 52

Drug Development Disease Therapies Engineering 52

Conversations in Drug Development Trends

OCTOBER 26, 2022

That’s because psychedelic trials are logistically heavy, requiring special licensing for drug handling, training for staff in Schedule I drug requirements, and standardized facilities. Certain licensing must be obtained. More guidance on safety considerations can be found, here.

Trials 97

Trials Clinical Trials Licensing Licensing 97

FDA Law Blog: Drug Discovery

MARCH 13, 2023

Bauer, Senior Regulatory Drug Expert & James E. Valentine — Incorporating patient and caregiver experiences into every phase of drug development has become increasingly prioritized during both development and review ( see, e.g. , previous coverage here ). By Larry J.

Therapies 98

Therapies Trials FDA Clinical Trials 98

Drug Target Review

APRIL 23, 2024

However, the high computing power, associated costs, and complexity of FEP mean it is not as widely adopted within the drug development industry as it should be. As a result, drug developers can expedite the path to clinical and commercial stages, meaning patients will receive essential treatments at accelerated rates.

Licensing 100

Licensing Licensing Drugs Drug Development 100

Predictive Oncology

MARCH 17, 2023

Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology out-licensor globally 150+ active licenses 160+ new drugs into early-phase clinical trials $647 million revenue from royalties & IP $2.8

Research 52

Research Clinical Trials Licensing Licensing 52

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. As soon as drug developers can begin to develop conviction, momentum increases. It’s a great example of how our model works.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Target Review

MARCH 4, 2025

Advancing drug development The implications of precision medicine in obesity care extend beyond selecting the right treatment for individual patients; it is also reshaping the development of next-generation obesity drugs.

Therapies 52

Therapies Treatment Clinical Trials Science 52

Predictive Oncology

MARCH 21, 2023

Pamela Bush of Predictive Oncology discuss the potential impact of their collaboration and how it can advance cancer drug development.

Research 52

Research Licensing Licensing Drugs 52

Perficient: Drug Development

SEPTEMBER 3, 2024

In the wake of VMware’s recent license cost increase under Broadcom’s new pricing model, many enterprises are facing the pressing need to reevaluate their IT strategies. Licensing is a critical yet often overlooked factor in cloud migration decisions.

Licensing 52

Licensing Licensing 52

Perficient: Drug Development

NOVEMBER 10, 2023

Depending on the size of the team and anticipated activity within a program, additional RDEs can also be provisioned, however, this may come at an additional licensing cost from Adobe. Creating an Rapid Development Environment The RDE can be provisioned with a Program via Cloud Manager in AEM as a Cloud Service.

Packaging 105

Packaging Licensing Licensing International 105

The Pharma Data

JANUARY 17, 2021

In particular, two new drugs developed by Hanmi Pharmaceutical Co., “Rolontis,” a treatment for neutropenia that had its technology licensed out to Spectrum Pharmaceuticals, Inc. and “Oraxol,” which was licensed out to Athenex, Inc. are expected to be approved by the U.S.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Perficient: Drug Development

AUGUST 12, 2024

Additionally, AIS often incurs significantly lower licensing and maintenance costs, making it an attractive option for organizations looking to optimize their IT expenditure. Azure Integration Services offers a more cost-effective solution compared to MuleSoft, primarily due to its consumption-based pricing model.

Compliance 105

Compliance Licensing Licensing Production 105

Molecule Blog

AUGUST 6, 2021

An Open Bazaar for Drug Development: Molecule Protocol The complexity of biopharma IP deals When examining the transactional market for biopharma IP, one aspect becomes immediately obvious: IP is not sold in a simple purchase agreement like houses, cars or other physical objects.

Licensing 52

Licensing Licensing Marketing Research 52

Perficient: Drug Development

JULY 6, 2023

Salesforce brings new technologies to the table with great features and functionality, but just buying a Salesforce license, standing up an organization, and finding a partner like Perficient to build are only part of the battle. Increasing Utilization By Addressing People and Processes Platforms are just one piece of the puzzle.

Licensing 98

Licensing Licensing Production 98

Perficient: Drug Development

AUGUST 2, 2023

SVS requires a license; we can utilize the same license as Sitecore TDS. If you don’t have a license, then you can purchase from the TDS site. For learning purposes, you can request a trial license as well. It provides all the features required for the serialization.

Packaging 52

Packaging Licensing Licensing Trials 52

Perficient: Drug Development

AUGUST 31, 2023

It is developed under the Apache 2.0 Google announced Kotlin is an official language for android development. Pre-Requisites Features of Kotlin Kotlin Architecture What is Kotlin? Kotlin is a programming language introduced by JetBrains in 2011. Kotlin is free, has been free and will remain free.

Licensing 105

Licensing Licensing International 105

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

This product was developed by uniQure prior to being licensed to CSL Behring.

Therapies 119

Therapies FDA FDA Approval Treatment 119

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. ” Under the license agreement, the development of ABBV-47D11 will be greatly advanced. Kate Krav-Rude/Shutterstock.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

Molecule Blog

JANUARY 9, 2023

IP-NFTs upgrade our legacy intellectual system by unifying IP (patents, legal), underlying data (through decentralized storage and access control), and economics (royalties, license fees, sales) into one programmable, transactable, digital unit. ‍ How will IP-NFTs enable drug development in the future?

Research 52

Research Licensing Licensing Science 52

The Pharma Data

NOVEMBER 8, 2020

The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. Inmagene is a leading drug development company focused on immunology-related therapeutic areas. To date, Inmagene has raised over $40 million financing.

Clinical Trials 40

Clinical Trials Licensing Licensing Drug Development 40

FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

While this hype may be warranted in some respects—a 60-year old legal provision has now been amended to acknowledge that the science of drug development is advancing—the change is mostly symbolic and is likely to take many years before we see it have a measurable impact. 42 U.S.C. § 262(k)(2)(A)(i)(I).

Animal Testing 64

Animal Testing Biosimilars Cell Based Assays FDA 64

Perficient: Drug Development

JUNE 1, 2024

Test with different license types : If the permission set is assigned to users with different license types, test it with each license type to ensure that the permissions work as expected.

Licensing 59

Licensing Licensing Production 59

LifeSciVC

JULY 17, 2024

By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drug development process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets.

Clinical Research 67

Clinical Research Disease Research Clinical Trials 67

Molecule Blog

AUGUST 19, 2021

In drug development however, when a therapeutic is discovered, or research becomes more akin to product development, the source of funding must change. These grants are utilised by researchers to get to the point of developing a potentially life-saving therapeutic. And this is the best-case scenario. for patents)?

Research 52

Research Licensing Licensing Drug Development 52